Medicare Enrolled

Dr. Anton Kolomeyer, MD, PHD

Ophthalmology · Vineland, NJ
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
251 S LINCOLN AVE, Vineland, NJ 08361
8566918188
In practice since 2013 (13 years)
NPI: 1245573864 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Kolomeyer from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kolomeyer? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Kolomeyer

Dr. Anton Kolomeyer is an ophthalmology specialist in Vineland, NJ, with 13 years of NPI registration. Based on federal Medicare data, Dr. Kolomeyer performed 20,280 Medicare services across 3,231 unique beneficiaries.

Between the years covered by Open Payments, Dr. Kolomeyer received a total of $241,276 from 23 pharmaceutical and/or device companies across 399 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in ophthalmology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Kolomeyer is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 13 years in practice ▲ Top 5% volume in NJ $241,276 industry payments

Medicare Practice Summary

Medicare Utilization ↗
20,280
Medicare services
Top 5% in NJ for ophthalmology
3,231
Unique beneficiaries
$90
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,560 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Eye injection (Vabysmo/faricimab)
An injection of faricimab-svoa, a medication administered in 0.1 mg doses.
12,600 $29 $124
Retinal imaging (OCT scan)
This procedure involves imaging the retina to visualize its structure. It is used to examine the back of the eye.
1,953 $33 $450
Comprehensive eye exam, established patient
A comprehensive examination of the visual system performed for a patient who has previously been seen by the provider.
1,704 $101 $366
Aflibercept eye injection (Eylea) 1,198 $680 $2,500
Eye injection for retinal disease
A procedure involving the administration of medication directly into the eye.
1,057 $98 $591
Extended exam of back of eye with optic nerve drawing
A detailed examination of the posterior section of the eye, including the optic nerve, with documentation through drawing.
465 $12 $115
Injection, ranibizumab, 0.1 mg 240 $187 $1,000
Compounded drug, not otherwise classified
A medication prepared specifically for an individual patient by a pharmacist or physician, tailored to meet unique needs that cannot be fulfilled by commercially available products.
162 $80 $802
Eye exam, established patient, focused
A limited examination of the visual system for an existing patient. The provider focuses on a specific eye-related concern or symptom.
136 $68 $259
Ranibizumab-eqrn injection, 0.1 mg
An injection of the biosimilar medication ranibizumab-eqrn (Cimerli) in a 0.1 mg dose.
135 $216 $1,000
Extended eye exam with retinal drawing
A detailed examination of the back of the eye that includes creating a drawing of the retina.
131 $20 $125
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
88 $56 $257
Comprehensive eye exam, new patient
A comprehensive examination of the visual system performed for a new patient.
82 $106 $431
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
75 $121 $470
Unclassified biologic
A biologic product that does not have a specific HCPCS code assigned.
61 $2,154 $6,607
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
52 $91 $362
Retinal photography (fundus photo)
This procedure involves taking photographs of the retina, the light-sensitive tissue at the back of the eye. It is used to document the condition of the eye's interior structures.
45 $29 $194
Ultrasound of eye tissue and structures
A diagnostic imaging test that uses sound waves to create pictures of the eye's internal tissues and structures.
42 $39 $263
Retinal laser treatment for leaking blood vessels
This procedure uses a laser to seal leaking blood vessels in the retina. It is performed to prevent vision loss caused by fluid leakage from damaged retinal vessels.
25 $246 $2,844
Unclassified drug
A medication that does not fit into standard HCPCS or CPT classification categories.
18 $1,921 $5,983
Retinal photocoagulation to prevent detachment
This procedure uses laser light to create small burns on the retina. It is performed to help prevent the retina from detaching from the back of the eye.
11 $174 $1,224
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$241,276
Total received (2018-2024)
Avg $34,468/year across 7 years
Top 2% in NJ for ophthalmology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
23
Companies
399
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$197,184 (81.7%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$40,340 (16.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,753 (1.6%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$71,827
2023
$90,838
2022
$40,672
2021
$5,223
2020
$8,604
2019
$23,719
2018
$392

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Astellas Pharma US Inc
$50,352
Regeneron Healthcare Solutions, Inc.
$19,225
Alimera Sciences, Inc.
$1,626
Biogen, Inc.
$175
Sandoz Inc.
$123
Genentech USA, Inc.
$84
ABBVIE INC.
$50
ANI Pharmaceuticals, Inc.
$50
Sight Sciences, Inc.
$38
Tarsus Pharmaceuticals, Inc.
$36
Coherus Biosciences Inc.
$31
Apellis Pharmaceuticals, Inc.
$19
SUN PHARMACEUTICAL INDUSTRIES INC.
$18
Top 3 companies account for 99.1% of 2024 payments
All-time payments by company (2018-2024) ›
Astellas Pharma US Inc
$66,578
Biogen, Inc.
$55,719
Genentech USA, Inc.
$36,030
Alimera Sciences, Inc.
$32,515
Regeneron Healthcare Solutions, Inc.
$24,897
ABBVIE INC.
$7,811
Allergan Inc.
$7,580
Genentech, Inc.
$3,960
Apellis Pharmaceuticals, Inc.
$3,827
Allergan, Inc.
$810
Coherus Biosciences Inc.
$411
Novartis Pharmaceuticals Corporation
$342
EyePoint Pharmaceuticals US, Inc.
$218
Sight Sciences, Inc.
$149
Aerie Pharmaceuticals, Inc.
$125
Sandoz Inc.
$123
ANI Pharmaceuticals, Inc.
$50
Tarsus Pharmaceuticals, Inc.
$36
Notal Vision, Inc.
$34
SUN PHARMACEUTICAL INDUSTRIES INC.
$18
Bausch & Lomb Americas Inc.
$16
Oyster Point Pharma, Inc.
$14
Kala Pharmaceuticals, Inc.
$12
Top 3 companies account for 65.6% of all-time payments
Associated products mentioned in payments ›
BEOVU · BYOOVIZ · COMBIGAN · Cequa · Cimerli · DUREZOL · EYLEA · EYLEA AFLIBERCEPT INJECTION · EYLEA HD · ILUVIEN · INVELTYS · Iluvien · Izervay · Lucentis · OMNI · OMNI SURGICAL SYSTEM · OZURDEX · PURIFIED CORTROPHIN GEL · Rhopressa · SUSVIMO · Syfovre · TYRVAYA · VABYSMO · Vabysmo · XDEMVY · XIPERE · YUTIQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (82%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in ophthalmology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for ophthalmology in NJ.

Looking for an ophthalmology specialist in Vineland?
Compare ophthalmologists in the Vineland area by procedure volume, costs, and industry payment transparency.
Browse ophthalmologists nearby

Geographic Context

Ophthalmologists within 10 mi
30
Per 100K population
19.6
County median income
$64,499
Nearest hospital
INSPIRA MEDICAL CENTER VINELAND
3.8 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Kolomeyer is a mixed practice specialist, with above-average Medicare volume (top 5% in NJ), with speaking/promotional industry engagement in the top 2% of NJ peers.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Kolomeyer experienced with eye injection (vabysmo/faricimab)?
Based on Medicare claims data, Dr. Kolomeyer performed 12,600 eye injection (vabysmo/faricimab) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kolomeyer receive payments from pharmaceutical companies?
Yes. Dr. Kolomeyer received a total of $241,276 from 23 companies across 399 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kolomeyer's costs compare to other ophthalmologists in Vineland?
Dr. Kolomeyer's average Medicare payment per service is $90. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kolomeyer) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →